BioCentury | Nov 9, 2019
Finance

Biotech investors wary of Warren tax proposals

...this alone will meaningfully disfavor investment in biotech over other industries,” Akkaraju said via email. WBB Securities’...
BioCentury | Oct 5, 2019
Finance

Seeking bright spots in 4Q19 amid continued underperformance

...far-reaching, the implications are so far-reaching, like never before. That’s the reality we face,” said WBB Securities’...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...in 3Q19 have at least made it into the clinic, with Viela Bio nearing commercialization. WBB Securities’...
BioCentury | Oct 2, 2019
Financial News

Three new IPO filings broaden fall queue

...fatten a queue that is growing again following a late-summer lull. “We’re seeing more IPOs,” WBB Securities'...
BioCentury | Dec 14, 2018
Financial News

Moderna raises $604M in record IPO, loses $1.4B in trading debut

...way they have pushed the boundaries of what we've seen in biotech." Steve Brozak of WBB Securities...
BioCentury | Dec 7, 2018
Financial News

Moderna loses $1.4B in trading debut

...way they have pushed the boundaries of what we've seen in biotech." Steve Brozak of WBB Securities...
BioCentury | Dec 7, 2018
Clinical News

RedHill planning NDA for H. pylori antibiotic following second Phase III readout

...underwritten by Ladenburg, Nomura, H.C. Wainwright, LifeSci Capital, Ascendiant Capital, SMBC Nikko Securities America and WBB Securities...
BioCentury | Nov 16, 2018
Finance

SVB Leerink’s full suite

...provide a retention pool of $60 million for employees to be paid over five years. WBB Securities’...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...is going well and access is good,” said Staijen. John Nolan and Steve Brozak of WBB Securities...
BioCentury | Jun 30, 2018
Finance

Smitten by SMID-caps

...there’s a fear they could overpay.” John Nolan, WBB John Nolan and Steve Brozak of WBB Securities...
Items per page:
1 - 10 of 48
BioCentury | Nov 9, 2019
Finance

Biotech investors wary of Warren tax proposals

...this alone will meaningfully disfavor investment in biotech over other industries,” Akkaraju said via email. WBB Securities’...
BioCentury | Oct 5, 2019
Finance

Seeking bright spots in 4Q19 amid continued underperformance

...far-reaching, the implications are so far-reaching, like never before. That’s the reality we face,” said WBB Securities’...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...in 3Q19 have at least made it into the clinic, with Viela Bio nearing commercialization. WBB Securities’...
BioCentury | Oct 2, 2019
Financial News

Three new IPO filings broaden fall queue

...fatten a queue that is growing again following a late-summer lull. “We’re seeing more IPOs,” WBB Securities'...
BioCentury | Dec 14, 2018
Financial News

Moderna raises $604M in record IPO, loses $1.4B in trading debut

...way they have pushed the boundaries of what we've seen in biotech." Steve Brozak of WBB Securities...
BioCentury | Dec 7, 2018
Financial News

Moderna loses $1.4B in trading debut

...way they have pushed the boundaries of what we've seen in biotech." Steve Brozak of WBB Securities...
BioCentury | Dec 7, 2018
Clinical News

RedHill planning NDA for H. pylori antibiotic following second Phase III readout

...underwritten by Ladenburg, Nomura, H.C. Wainwright, LifeSci Capital, Ascendiant Capital, SMBC Nikko Securities America and WBB Securities...
BioCentury | Nov 16, 2018
Finance

SVB Leerink’s full suite

...provide a retention pool of $60 million for employees to be paid over five years. WBB Securities’...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...is going well and access is good,” said Staijen. John Nolan and Steve Brozak of WBB Securities...
BioCentury | Jun 30, 2018
Finance

Smitten by SMID-caps

...there’s a fear they could overpay.” John Nolan, WBB John Nolan and Steve Brozak of WBB Securities...
Items per page:
1 - 10 of 48